Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY:MRK)

82.39 +0.58 (+0.71%)
Official Closing Price Updated: 6:30 PM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
What's going on in today's session: S&P500 movers
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK).
Uncovering Dividend Opportunities with MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck & Co Unusual Options Activity
Via Benzinga
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Via The Motley Fool
Topics Economy Government Stocks
8 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Merck & Co. Inc. (NYSE:MRK): A Potential Undervalued Opportunity
Merck & Co. Inc. (NYSE:MRK): A Potential Undervalued Opportunity 
Via Chartmill
Should Investors Buy Merck Stock After These Huge Risks?
Via The Motley Fool
Stock Market Crash: 3 High-Yielding Dividend Stocks Near Their 52-Week Lows to Buy Right Now
Via The Motley Fool
Topics Government World Trade
How To Put $100 In Your Retirement Fund Each Month With Merck Stock
Via Benzinga
Topics Retirement
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Why Is Summit Therapeutics Stock Trading Higher On Monday?
Summit Therapeutics highlights China approval of Akeso's ivonescimab for NSCLC, with enrollment ongoing for Phase 3 HARMONi-7 trial. 
Via Benzinga
Merck Germany Buys US Cancer Drugmaker SpringWorks Therapeutics For Around $4 Billion
Merck & Company, Inc. (MRK) to acquire SpringWorks Therapeutics, Inc. (SWTX) for $47/share in cash, creating synergies for rare tumor treatments and immediate revenue growth. 
Via Benzinga
Despite its impressive fundamentals,MERCK & CO. INC. (NYSE:MRK) remains undervalued.
Discover MERCK & CO. INC., an undervalued stock. NYSE:MRK showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
Pfizer (PFE) Reports Q1: Everything You Need To Know Ahead Of Earnings
Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting earnings tomorrow before market hours. Here’s what you need to know. 
Via StockStory
Topics Government World Trade
2 Outstanding Dividend Stocks to Buy and Hold For 20 Years
Via The Motley Fool
Topics Government World Trade
These S&P500 stocks are moving in today's session
Curious about the top performers within the S&P500 index one hour before the close of the markets on Friday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
Merck Stays Confident On M&A Despite Market Uncertainty: Analyst
Merck projects $200 million in tariff costs, boosts U.S. manufacturing plans, and continues M&A efforts amid external pressures and shifting market dynamics. 
Via Benzinga
Topics World Trade
What's Going On With Summit Therapeutics Stock On Friday?
Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in lung cancer trials. 
Via Benzinga
Market Monitor April 25 ( Texas Instruments, Nvidia & Amazon UP, IBM, PepsiCo & Comcast DOWN)
Wall Street Rallies Again: Tech Leads the Charge, Alphabet Shines After-Hours 
Via Chartmill
Merck (MRK) Q1 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings World Trade
Halozyme Sues Merck Over Subcutaneous Keytruda Formulation, Seeks Injunctive Relief
Halozyme said that it believes the subcutaneous formulation of Merck's cancer medicine Keytruda infringes multiple patents that Halozyme filed beginning in 2011 to protect its groundbreaking MDASE... 
Via Stocktwits
Topics Intellectual Property Lawsuit
Merck's Q1 Earnings Beat Wall Street, Adjusts 2025 Profit Outlook As Tariffs May Result In Incremental Cost Of $200 Million
Merck posted Q1 adjusted EPS of $2.22 and revenue of $15.53 billion, beating estimates while revising full-year guidance amid tariff-related cost pressure. 
Via Benzinga
Topics Earnings
Merck & Co. Reports Better Than Expected Results For First-Quarter 2025
Merck's Q1 2025 results show a slight decrease in total sales but highlight growth in key segments. 
Via Talk Markets
Topics Stocks / Equities
Durable Goods Orders Jump 9.2% In March, But One Category Tells The Real Story
US durable goods orders surged in March, but with a mixed picture. Transportation equipment led the gain, while other sectors showed minimal growth or decline. 
Via Benzinga
Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday?
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade... 
Via Benzinga
Topics Government World Trade
Merck Reports Strong Q1 Earnings But Downgrades Full-Year Guidance: Retail Sentiment Brightens
Merck estimates that the impact of tariffs implemented to date will result in incremental costs of approximately $200 million. 
Via Stocktwits
Topics Government World Trade
Merck’s (NYSE:MRK) Q1 Sales Beat Estimates
Global pharmaceutical company Merck (NYSE:MRK) beat Wall Street’s revenue expectations in Q1 CY2025, but sales fell by 1.6% year on year to $15.53 billion. The company expects the full year’s revenue... 
Via StockStory
Topics Artificial Intelligence Earnings Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9
...
87 88 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.